Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Revenue (2016 - 2025)

Historic Revenue for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to $351000.0.

  • Seres Therapeutics' Revenue changed N/A to $351000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $351000.0, marking a year-over-year increase of 44843.75%. This contributed to the annual value of $126.3 million for FY2023, which is 167223.63% up from last year.
  • As of Q3 2025, Seres Therapeutics' Revenue stood at $351000.0.
  • Over the past 5 years, Seres Therapeutics' Revenue peaked at $126.7 million during Q3 2021, and registered a low of $64000.0 during Q4 2023.
  • For the 4-year period, Seres Therapeutics' Revenue averaged around $21.5 million, with its median value being $1.5 million (2022).
  • As far as peak fluctuations go, Seres Therapeutics' Revenue crashed by 9728.23% in 2022, and later skyrocketed by 1030074.01% in 2023.
  • Quarter analysis of 4 years shows Seres Therapeutics' Revenue stood at $7.2 million in 2021, then plummeted by 86.5% to $975000.0 in 2022, then plummeted by 93.44% to $64000.0 in 2023, then skyrocketed by 448.44% to $351000.0 in 2025.
  • Its Revenue stands at $351000.0 for Q3 2025, versus $64000.0 for Q4 2023 and $310000.0 for Q3 2023.